Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Novartis

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novartis' 2013 sales performance.

Novartis

Roche’s Ocrevus shows significant benefit in early-stage MS patients

Roche’s Ocrevus shows significant benefit in early-stage MS patients The early-stage data bolsters Ocrevus’ claim in the crowded MS market, particularly against Novartis’ Kesimpta (ofatumumab).

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses The CD20 monoclonal antibody (mAb) was originally developed by Danish biotech company Genmab, and subsequently developed and marketed worldwide by Novartis under a licence agreement. ... According to Genmab, Kesimpta is the first B-cell therapy that can

CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval

CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval To support the planned rollout of its COVID-19 jab, CureVac has signed a number of strategic agreements, including with Novartis and Bayer. ... Novartis plans to manufacture the mRNA and bulk drug product of CureVac's CVnCoV for up to 50 million doses by

Novartis agrees to help produce Roche’s repurposed COVID-19 drug

Novartis agrees to help produce Roche’s repurposed COVID-19 drug Novartis will make ingredients for Actemra/RoActemra, which is being investigated in COVID-19. ... Novartis has signed an initial agreement with Roche to help produce its repurposed COVID-19 treatment Actemra/RoActemra.

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC At 12 months, the PFS rate was 23.3% for patients receiving BeiGene/Novartis’ therapy versus 5.7% in the docetaxel arm. ... added. In January, Novartis and BeiGene signed a strategic collaboration agreement for the Swiss pharma company to in-license

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...